Source: Annual Congress 2010 - The role of biomarkers in lung cancer
Disease area: Thoracic oncology



Rating:

Share or cite this content

Citations should be made in the following way:
K. Darwiche, J. I. Baumbach, B. Boedeker, S. Welter, T. Gauler, L. Freitag (Dortmund, Germany). Volatile organic compounds (VOC) in non-small-cell lung cancer (NSCLC). Eur Respir J 2010; 36: Suppl. 54, 1947

Member's Comments

No comment yet.

Related content which might interest you: Volatile organic compounds (VOCs) in exhaled air of patients with lung cancer Source: Eur Respir J 2003; 22: Suppl. 45, 208s Year: 2003 Volatile organic compounds in lung cancer patients before and after tumour resection Source: Annual Congress 2011 - Biomarkers and other new methods for lung cancer Year: 2011 Differences in volatile organic compounds (VOC) determined in exhaled breath in two populations of lung cancer (LC): With and without COPD Source: Annual Congress 2013 –New methods for diagnostic workup of lung cancer Year: 2013 New contributions in the determination of volatile organic compounds (VOC) in lung cancer (LC) Source: Annual Congress 2011 - Biomarkers and other new methods for lung cancer Year: 2011 Presence of volatile organic compounds (VOC) in exhaled breath in patients diagnosed with lung cancer (LC) vs healthy patients. Preliminary data Source: Annual Congress 2010 - Biomarkers for lung cancer Year: 2010 Comparing exhaled molecular profiles of patients with non-small cell lung cancer (NSCLC) with those of patients with non-pulmonary malignancy Source: Annual Congress 2010 - Exhaled biomarkers: smells like disease Year: 2010 Role of chemokines in resectable non-small cell lung cancer (NSCLC) Source: International Congress 2019 – Biology and prognosis of lung cancer Year: 2019 Treatment of  non-small cell lung cancer (NSCLC) - the state of the art and beyond Source: International Congress 2017 – State of the art session: "Lung cancer" Year: 2017 24h-blood profile gene expression biomarkers of the response to bevacizumab-erlotinib (BE) in advanced non-squamous non-small cell lung cancer (NSCLC) Source: International Congress 2016 – Therapeutic trials in lung cancer Year: 2016 Predictive role of plasmatic biomarkers in advanced non-small cell lung cancer (NSCLC) treated with nivolumab (nivo). Source: International Congress 2018 – Lung cancer: new aspects in diagnosis and management Year: 2018 Induction chemotherapy (IC) followed by surgery (S) for advanced non-small cell lung cancer (NSCLC) Source: Eur Respir J 2002; 20: Suppl. 38, 463s Year: 2002 Hyper-progressive disease in patients with advanced non-small cell lung cancer (NSCLC) treated with nivolumab (nivo) Source: International Congress 2018 – Lung cancer: modern therapies and beyond Year: 2018 Non-small cells lung cancer (NSCLC) in non-smokers (NS) – sharing experience Source: International Congress 2017 – Smoking and health hazards Year: 2017 Radiotherapy for stage III non-small cell lung cancer (NSCLC) Source: European Multidisciplinary Conference in Thoracic Oncology 2009 Year: 2009 Volatile organic compounds (VOC) in exhaled air sampled through the working channel of a bronchoscope in lung cancer patients Source: Annual Congress 2010 - Recent developments of molecular pathology and functional genomics in non-neoplastic and neoplastic lung diseases Year: 2010 Volatile organic compounds (VOC) in exhaled breath in patients with lung cancer, using the analytical technique thermal desorber- gase chromatography-spectrometer mases Source: Annual Congress 2012 - New biomarkers for lung cancer Year: 2012 Docetaxel (DOC) and gemcitabine (GEM) consist a safe and effective combination in the management of non-small cell lung cancer (NSCLC) Source: Eur Respir J 2003; 22: Suppl. 45, 30s Year: 2003 Risk factor for survival in never-smokers non-small cell lung cancer (NSCLC) Source: Annual Congress 2010 - Thoracic malignancies: interesting case studies and series Year: 2010 Gemcitabine and cisplatin ( GD) as first line chemotherapy in patients with non-small-cell lung cancer (NSCLC) Source: Eur Respir J 2002; 20: Suppl. 38, 464s Year: 2002 How to predict fatal pneumonitis in non-small cell lung cancer (NSCLC) patients treated with radiotherapy (RT) Source: International Congress 2018 – Lung cancer: modern therapies and beyond Year: 2018